Several genetic mutations, such as EGFR, HER2, MET and fusion oncogenes involving anaplastic lymphoma kinase (ALK), ROS1 and RET, have been identified and validated as oncogenic drivers, able to determine the development and maintenance of specific subclasses of NSCLC [35, 36]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.